Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma
A single dose of neoadjuvant pembrolizumab is a safe and feasible approach with potential for early pathological readout of responsiveness to neoadjuvant therapy. Late recurrences were observed in the MPR group, indicating need for follow-up but were salvageable. Further biomarker work is needed to identify patients who would benefit from neoadjuvant single agent anti-PD-1 therapy.
Authors
- John T. Miura (ORCID: https://orcid.org/0000-0001-7028-2152)
- Ravi K. Amaravadi (ORCID: https://orcid.org/0000-0002-5768-2474)
- Tara C. Mitchell (ORCID: https://orcid.org/0000-0002-8186-7284)
- Lynn M. Schuchter
- Mohammad Saad Farooq (ORCID: https://orcid.org/0009-0009-8493-6976)
- Neha Shafique (ORCID: https://orcid.org/0000-0001-7219-2839)
- G Vargas (ORCID: https://orcid.org/0000-0002-5963-4513)
- Xiaowei Xu (ORCID: https://orcid.org/0000-0003-4098-7690)
- Giorgos C. Karakousis
- Valentina Mattfeld
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1245/s10434-025-18314-5
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09